Drug intelligence / Profile preview

TRK-001 + tacrolimus

Development stage
Unknown
Lead developer
Tract Therapeutics
Modality
Small Molecules
Administration
Oral, Intravenous, Topical
01

Overview

TRK-001 + tacrolimus is a combination drug consisting of TRK-001 and tacrolimus. Tacrolimus is a small-molecule immunosuppressant, specifically a calcineurin inhibitor, used primarily to prevent organ transplant rejection. It inhibits T-cell activation by binding to FKBP-12, forming a complex that inhibits calcineurin phosphatase activity, resulting in reduced transcription of interleukin-2 and other cytokines and blocking the progression of T cells from the G0 to G1 phase[3][4][1]. No definitive information is available in the provided data regarding TRK-001’s mechanism, structure, or clinical indications when used in combination with tacrolimus. As a result, the description is limited to the known properties of tacrolimus and the structure of the combination.

Brand names
AstagrafEnvarsusModigrafTacforius
Other names
FK-506FK506FK 506fujimycintacroTacrolimus anhydrousK506K-506K 506
02

Targets

FKBP1ACN (Calcineurin)

Beyond the preview

Go deeper on TRK-001 + tacrolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRK-001 + tacrolimus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call